XNCR / Xencor: Data In Early 2024 Could Bring Shareholder Value

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate sh more_horizontal

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li more_horizontal

Xencor, Inc. (NASDAQ:XNCR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communic more_horizontal

Xencor (XNCR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.57 more_horizontal

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki more_horizontal

Xencor (XNCR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to earnings of $ more_horizontal

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokin more_horizontal